291 related articles for article (PubMed ID: 29424441)
1. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial.
Gybel-Brask M; Seeberg J; Thomsen LL; Johansson PI
Transfusion; 2018 Apr; 58(4):974-981. PubMed ID: 29424441
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
[TBL] [Abstract][Full Text] [Related]
3. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
4. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
Stein J; Walper A; Klemm W; Farrag K; Aksan A; Dignass A
Scand J Gastroenterol; 2018 Sep; 53(9):1059-1065. PubMed ID: 30222479
[TBL] [Abstract][Full Text] [Related]
6. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
Reinisch W; Staun M; Tandon RK; Altorjay I; Thillainayagam AV; Gratzer C; Nijhawan S; Thomsen LL
Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
[TBL] [Abstract][Full Text] [Related]
7. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.
Charles-Edwards G; Amaral N; Sleigh A; Ayis S; Catibog N; McDonagh T; Monaghan M; Amin-Youssef G; Kemp GJ; Shah AM; Okonko DO
Circulation; 2019 May; 139(21):2386-2398. PubMed ID: 30776909
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
Bhandari S; Kalra PA; Kothari J; Ambühl PM; Christensen JH; Essaian AM; Thomsen LL; Macdougall IC; Coyne DW
Nephrol Dial Transplant; 2015 Sep; 30(9):1577-89. PubMed ID: 25925701
[TBL] [Abstract][Full Text] [Related]
9. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
Derman R; Roman E; Modiano MR; Achebe MM; Thomsen LL; Auerbach M
Am J Hematol; 2017 Mar; 92(3):286-291. PubMed ID: 28052413
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
Kalra PA; Bhandari S; Saxena S; Agarwal D; Wirtz G; Kletzmayr J; Thomsen LL; Coyne DW
Nephrol Dial Transplant; 2016 Apr; 31(4):646-55. PubMed ID: 26250435
[TBL] [Abstract][Full Text] [Related]
12. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease.
Kalra PA; Bhandari S; Spyridon M; Davison R; Lawman S; Mikhail A; Reaich D; Pritchard N; McCafferty K; Moore J
BMC Nephrol; 2020 Dec; 21(1):539. PubMed ID: 33302891
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial).
Johansson PI; Rasmussen AS; Thomsen LL
Vox Sang; 2015 Oct; 109(3):257-66. PubMed ID: 25900643
[TBL] [Abstract][Full Text] [Related]
14. Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial.
Holm C; Thomsen LL; Norgaard A; Langhoff-Roos J
Trials; 2015 Jan; 16():5. PubMed ID: 25588587
[TBL] [Abstract][Full Text] [Related]
15. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
Dahlerup JF; Jacobsen BA; van der Woude J; Bark LÅ; Thomsen LL; Lindgren S
Scand J Gastroenterol; 2016 Nov; 51(11):1332-8. PubMed ID: 27326766
[TBL] [Abstract][Full Text] [Related]
16. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)
.
Jensen G; Gøransson LG; Fernström A; Furuland H; Christensen JH
Clin Nephrol; 2019 Apr; 91(4):246-253. PubMed ID: 30614439
[TBL] [Abstract][Full Text] [Related]
17. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
[TBL] [Abstract][Full Text] [Related]
18. A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia
.
Biggar P; Leistikow F; Walper A
Clin Nephrol; 2016 Dec; 86 (2016)(12):310-318. PubMed ID: 27737531
[TBL] [Abstract][Full Text] [Related]
19. Iron (III) isomaltoside 1000.
Mace TA; Syed A; Bhandari S
Expert Rev Hematol; 2013 Jun; 6(3):239-46. PubMed ID: 23782077
[TBL] [Abstract][Full Text] [Related]
20. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
Pollock RF; Muduma G
Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
